Evidence for Neuroprotective Effects of Antipsychotic Drugs: Implications for the Pathophysiology and Treatment of Schizophrenia

International Review of Neurobiology

Volumn 77, Issue , 2007, Pages 107-142

  Li, Xin Min ^a   Xu, Haiyun ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33845416850     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(06)77004-0     Document Type: Review

References (234)

1. Addy N.A., Pocivavsek A., and Levin E.D. Reversal of clozapine effects on working memory in rats with fimbria-fornix lesions. Neuropsychopharmacology 30 (2005) 1121-1127
2. Adityanjee, and Schulz S.C. Clinical use of quetiapine in disease states other than schizophrenia. J. Clin. Psychiatry 63 Suppl. 13 (2002) 32-38
3. Alberch J., Brito B., Notario V., and Castro R. Prenatal haloperidol treatment decreases nerve growth factor receptor and mRNA in neonate rat forebrain. Neurosci. Lett. 131 (1991) 228-232
4. Alleva E., Della Seta D., Cirulli F., and Aloe L. Haloperidol treatment decreases nerve growth factor levels in the hypothalamus of adult mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 20 (1996) 483-489
5. An J.J., Cho S.R., Jeong D.W., Park K.W., Ahn Y.S., and Baik J.H. Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells. Mol. Cell. Endocrinol. 206 (2003) 49-62
6. Andreasen N.C. Symptoms, signs, and diagnosis of schizophrenia. Lancet 346 (1995) 477-481
7. Andreasen N.C., Nopoulos P., Schultz S., Miller D., Gupta S., Swayze V., and Flaum M. Positive and negative symptoms of schizophrenia: Past, present, and future. Acta Psychiatr. Scand. 384 Suppl. (1994) 51-59
8. Angelucci F., Aloe L., Gruber S.H., Fiore M., and Mathe A.A. Chronic antipsychotic treatment selectively alters nerve growth factor and neuropeptide Y immunoreactivity and the distribution of choline acetyl transferase in rat brain regions. Int. J. Neuropsychopharmacol. 3 (2000) 13-25
9. Angelucci F., Mathe A.A., and Aloe L. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. J. Neurosci. Res. 60 (2000) 783-794
10. Angelucci F., Aloe L., Iannitelli A., Gruber S.H., and Mathe A.A. Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brain. Eur. Neuropsychopharmacol. 15 (2005) 311-317
11. Antonova E., Sharma T., Morris R., and Kumari V. The relationship between brain structure and neurocognition in schizophrenia: A selective review. Schizophr. Res. 70 (2004) 117-145
12. Arita J., Hashi A., Hoshi K., Mazawa S., and Suzuki S. D2 dopamine-receptor-mediated inhibition of proliferation of rat lactotropes in culture is accompanied by changes in cell shape. Neuroendocrinology 68 (1998) 163-171
13. Arnold S.E. Cellular and molecular neuropathology of the parahippocampal region in schizophrenia. Ann. NY Acad. Sci. 911 (2000) 275-292
14. Bachmann R.F., Schloesser R.J., Gould T.D., and Manji H.K. Mood stabilizers target cellular plasticity and resilience cascades: Implications for the development of novel therapeutics. Mol. Neurobiol. 32 (2005) 173-202
15. Backhouse B., Barochovsky O., Malik C., Patel A.J., and Lewis P.D. Effects of haloperidol on cell proliferation in the early postnatal rat brain. Neuropathol. Appl. Neurobiol. 8 (1982) 109-116
16. Bai O., Xu H., and Li X.M. Haloperidol and atypical antipsychotics share a same action of decreasing p75NTR mRNA levels in PC12 cells. Life Sci. 79 (2006) 570-574
17. Bai O., Wei Z., Lu W., Bowen R., Keegan D., and Li X.M. Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal. J. Neurosci. Res. 69 (2002) 278-283
18. Bai O., Chlan-Fourney J., Bowen R., Keegan D., and Li X.M. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J. Neurosci. Res. 71 (2003) 127-131
19. Banasr M., Hery M., Printemps R., and Daszuta A. Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone. Neuropsychopharmacology 29 (2004) 450-460
20. Barbee J.G., Conrad E.J., and Jamhour N.J. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J. Clin. Psychiatry 65 (2004) 975-981
21. Bardgett M.E., Griffith M.S., Foltz R.F., Hopkins J.A., Massie C.M., and O'Connell S.M. The effects of clozapine on delayed spatial alternation deficits in rats with hippocampal damage. Neurobiol. Learn. Mem. 85 (2006) 86-94
22. Barochovsky O., and Patel A.J. Effect of central nervous system acting drugs on brain cell replication in vitro. Neurochem. Res. 7 (1982) 1059-1074
23. Bersani G., Iannitelli A., Fiore M., Angelucci F., and Aloe L. Data and hypotheses on the role of nerve growth factor and other neurotrophins in psychiatric disorders. Med. Hypotheses 55 (2000) 199-207
24. Bersani G., Iannitelli A., Massoni E., Garavini A., Grilli A., Di Giannantonio M., Conti C.M., and Pancheri P. Ultradian variation of nerve growth factor plasma levels in healthy and schizophrenic subjects. Int. J. Immunopathol. Pharmacol. 17 (2004) 367-372
25. Bogan A.M., Koran L.M., Chuong H.W., Vapnik T., and Bystritsky A. Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: An open-label study. J. Clin. Psychiatry 66 (2005) 73-79
26. Breier A. Cognitive deficit in schizophrenia and its neurochemical basis. Br. J. Psychiatry 174 Suppl. 37 (1999) 16-18
27. Breier A., Kirkpatrick B., and Buchanan R.W. Clozapine attenuates meta-chlorophenylpiperazine (mCPP)-induced plasma cortisol increases in schizophrenia. Biol. Psychiatry 34 (1993) 492-494
28. Calabrese J.R., Keck Jr. P.E., Macfadden W., Minkwitz M., Ketter T.A., Weisler R.H., Cutler A.J., McCoy R., Wilson E., and Mullen J. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am. J. Psychiatry 162 (2005) 1351-1360
29. Cameron H.A., and McKay R.D. Adult neurogenesis produces a large pool of new granule cells in the dentate gyrus. J. Comp. Neurol. 435 (2001) 406-417
30. Carey P.D., Vythilingum B., Seedat S., Muller J.E., van Ameringen M., and Stein D.J. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: A double-blind, randomised, placebo-controlled study [ISRCTN83050762]. BMC Psychiatry 5 (2005) 5
31. Cavus I., and Duman R.S. Influence of estradiol, stress, and 5-HT2A agonist treatment on brain-derived neurotrophic factor expression in female rats. Biol. Psychiatry 54 (2003) 59-69
32. Chaturvedi R.K., Shukla S., Seth K., and Agrawal A.K. Nerve growth factor increases survival of dopaminergic graft, rescue nigral dopaminergic neurons and restores functional deficits in rat model of Parkinson's disease. Neurosci. Lett. 398 (2006) 44-49
33. Chen Z., Xu H., Haimanot S., Li X., and Li X.M. Quetiapine and venlafaxine synergically regulate heme oxygenase-2 protein expression in hippocampal formations of stressed rats. Neurosci. Lett. 389 (2005) 173-177
34. Chien K.R., Peau R.G., and Farber J.L. Ischemic myocardial cell injury. Prevention by chlorpromazine of an accelerated phospholipid degradation and associated membrane dysfunction. Am. J. Pathol. 97 (1979) 505-529
35. Chlan-Fourney J., Ashe P., Nylen K., Juorio A.V., and Li X.M. Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration. Brain Res. 954 (2002) 11-20
36. Chou Y.H., Halldin C., and Farde L. Occupancy of 5-HT1A receptors by clozapine in the primate brain: A PET study. Psychopharmacology (Berl.) 166 (2003) 234-240
37. Chuang D.M. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: Can it be used to treat neurodegenerative diseases?. Crit. Rev. Neurobiol. 16 (2004) 83-90
38. Chung Y.C., Li Z., Dai J., Meltzer H.Y., and Ichikawa J. Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: Role of 5-HT1A receptor agonism. Brain Res. 1023 (2004) 54-63
39. Ciani E., Virgili M., and Contestabile A. Akt pathway mediates a cGMP-dependent survival role of nitric oxide in cerebellar granule neurones. J. Neurochem. 81 (2002) 218-228
40. Cohrs S., Pohlmann K., Guan Z., Jordan W., Meier A., Huether G., Ruther E., and Rodenbeck A. Quetiapine reduces nocturnal urinary cortisol excretion in healthy subjects. Psychopharmacology (Berl.) 174 (2004) 414-420
41. Condorelli D.F., Dell'Albani P., Mudo G., Timmusk T., and Belluardo N. Expression of neurotrophins and their receptors in primary astroglial cultures: Induction by cyclic AMP-elevating agents. J. Neurochem. 63 (1994) 509-516
42. Connor B., and Dragunow M. The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res. Brain Res. Rev. 27 (1998) 1-39
43. Corcoran C., Gallitano A., Leitman D., and Malaspina D. The neurobiology of the stress cascade and its potential relevance for schizophrenia. J. Psychiatr. Pract. 7 (2001) 3-14
44. Corso T.D., Sesma M.A., Tenkova T.I., Der T.C., Wozniak D.F., Farber N.B., and Olney J.W. Multifocal brain damage induced by phencyclidine is augmented by pilocarpine. Brain Res. 752 (1997) 1-14
45. Cosi C., Waget A., Rollet K., Tesori V., and Newman-Tancredi A. Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: Role of 5-HT1A receptor activation. Brain Res. 1043 (2005) 32-41
46. Csernansky J.G., Humphrey W.M., Jefferson A., and Bardgett M.E. Risperidone restores memory deficits in rats with excitotoxin-induced hippocampal neuropathy. Hawaii Poster presented at the 40th Meeting of the ACNP, Waikoloa, Hawaii. December 9-13, 2001 (2001)
47. Csernansky J.G., Mahmoud R., Brenner R., and Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med. 346 (2002) 16-22
48. Cussac D., Duqueyroix D., Newman-Tancredi A., and Millan M.J. Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h)serotonin (5-HT)(1A) receptors. Psychopharmacology (Berl.) 162 (2002) 168-177
49. Dakhale G., Khanzode S., Khanzode S., Saoji A., Khobragade L., and Turankar A. Oxidative damage and schizophrenia: The potential benefit by atypical antipsychotics. Neuropsychobiology 49 (2004) 205-209
50. Dalla Libera A., Scutari G., Boscolo R., Rigobello M.P., and Bindoli A. Antioxidant properties of clozapine and related neuroleptics. Free Radic. Res. 29 (1998) 151-157
51. Dawirs R.R., Hildebrandt K., and Teuchert-Noodt G. Adult treatment with haloperidol increases dentate granule cell proliferation in the gerbil hippocampus. J. Neural. Transm. 105 (1998) 317-327
52. Dawson N.M., Hamid E.H., Egan M.F., and Meredith G.E. Changes in the pattern of brain-derived neurotrophic factor immunoreactivity in the rat brain after acute and subchronic haloperidol treatment. Synapse 39 (2001) 70-81
53. De Deyn P.P., Carrasco M.M., Deberdt W., Jeandel C., Hay D.P., Feldman P.D., Young C.A., Lehman D.L., and Breier A. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int. J. Geriatr. Psychiatry 19 (2004) 115-126
54. Denys D., van Megen H., and Westenberg H. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: An open-label study. J. Clin. Psychiatry 63 (2002) 700-703
55. Denys D., de Geus F., van Megen H.J., and Westenberg H.G. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J. Clin. Psychiatry 65 (2004) 1040-1048
56. DeSilva C.C., Nurse M.C., and Vokey K. Steroid-induced psychosis treated with risperidone. Can. J. Psychiatry 47 (2002) 388-389
57. Diaz-Mataix L., Artigas F., and Celada P. Activation of pyramidal cells in rat medial prefrontal cortex projecting to ventral tegmental area by a 5-HT(1A) receptor agonist. Eur. Neuropsychopharmacol. 16 (2006) 288-296
58. Dickerson J., and Sharp F.R. Atypical antipsychotics and a Src kinase inhibitor (PP1) prevent cortical injury produced by the psychomimetic, noncompetitive NMDA receptor antagonist MK-801. Neuropsychopharmacol. 31 (2006) 1420-1430
59. Dobyan D.C., and Bulger R.E. Partial protection by chlorpromazine in mercuric chloride-induced acute renal failure in rats. Lab. Invest. 50 (1984) 578-586
60. Dono R. Fibroblast growth factors as regulators of central nervous system development and function. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284 (2003) R867-R881
61. Dudek H., Datta S.R., Franke T.F., Birnbaum M.J., Yao R., Cooper G.M., Segal R.A., Kaplan D.R., and Greenberg M.E. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science. 275 (1997) 661-665
62. Duman R.S. Novel therapeutic approaches beyond the serotonin receptor. Biol. Psychiatry 44 (1998) 324-335
63. Duman R.S., Heninger G.R., and Nestler E.J. A molecular and cellular theory of depression. Arch. Gen. Psychiatry 54 (1997) 597-606
64. Durany N., Michel T., Zochling R., Boissl K.W., Cruz-Sanchez F.F., Riederer P., and Thome J. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr. Res. 52 (2001) 79-86
65. Ellenbroek B.A. Treatment of schizophrenia: A clinical and preclinical evaluation of neuroleptic drugs. Pharmacol. Ther. 57 (1993) 1-78
66. Ellison G. Stimulant-induced psychosis, the dopamine theory of schizophrenia, and the habenula. Brain Res. Brain Res. Rev. 19 (1994) 223-239
67. Ellison G., and Switzer III R.C. Dissimilar patterns of degeneration in brain following four different addictive stimulants. Neuroreport 5 (1993) 17-20
68. Ernfors P., Ibanez C.F., Ebendal T., Olson L., and Persson H. Molecular cloning and neurotrophic activities of a protein with structural similarities to nerve growth factor: Developmental and topographical expression in the brain. Proc. Natl. Acad. Sci. USA 87 (1990) 5454-5458
69. Farber J.L., Martin J.T., and Chien K.R. Irreversible ischemic cell injury. Prevention by chlorpromazine of the aggregation of the intramembranous particles of rat liver plasma membranes. Am. J. Pathol. 92 (1978) 713-732
70. Farber N.B., Price M.T., Labruyere J., Nemnich J., St. Peter H., Wozniak D.F., and Olney J.W. Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity. Biol. Psychiatry 34 (1993) 119-121
71. Farber N.B., Foster J., Duhan N.L., and Olney J.W. Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity. Schizophr. Res. 21 (1996) 33-37
72. Farber N.B., Hanslick J., Kirby C., McWilliams L., and Olney J.W. Serotonergic agents that activate 5HT2A receptors prevent NMDA antagonist neurotoxicity. Neuropsychopharmacology 18 (1998) 57-62
73. Fix A.S., Horn J.W., Wightman K.A., Johnson C.A., Long G.G., Storts R.W., Farber N., Wozniak D.F., and Olney J.W. Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): A light and electron microscopic evaluation of the rat retrosplenial cortex. Exp. Neurol. 123 (1993) 204-215
74. Fujikawa T., Takahashi T., Kinoshita A., Kajiyama H., Kurata A., Yamashita H., and Yamawaki S. Quetiapine treatment for behavioral and psychological symptoms in patients with senile dementia of Alzheimer type. Neuropsychobiology 49 (2004) 201-204
75. Fujimura M., Hashimoto K., and Yamagami K. Effects of antipsychotic drugs on neurotoxicity, expression of fos-like protein and c-fos mRNA in the retrosplenial cortex after administration of dizocilpine. Eur. J. Pharmacol. 398 (2000) 1-10
76. Fumagalli F., Molteni R., Bedogni F., Gennarelli M., Perez J., Racagni G., and Riva M.A. Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801. Neuroreport 15 (2004) 2109-2112
77. Galili-Mosberg R., Gil-Ad I., Weizman A., Melamed E., and Offen D. Haloperidol-induced neurotoxicity-possible implications for tardive dyskinesia. J. Neural. Transm. 107 (2000) 479-490
78. Ghaemi S.N., Cherry E.L., Katzow J.A., and Goodwin F.K. Does olanzapine have antidepressant properties? A retrospective preliminary study. Bipolar Disord. 2 (2000) 196-199
79. Ghaemi S.N., Hsu D.J., Rosenquist K.J., Katzow J.J., and Goodwin F.K. Long-term observational comparison of risperidone and olanzapine in bipolar disorder. Ann. Clin. Psychiatry 16 (2004) 69-73
80. Gould E., Tanapat P., Hastings N.B., and Shors T.J. Neurogenesis in adulthood: A possible role in learning. Trends Cogn. Sci. 3 (1999) 186-192
81. Halim N.D., Weickert C.S., McClintock B.W., Weinberger D.R., and Lipska B.K. Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus. Neuropsychopharmacology 29 (2004) 1063-1069
82. Harris M.E., Carney J.M., Cole P.S., Hensley K., Howard B.J., Martin L., Bummer P., Wang Y., Pedigo Jr. N.W., and Butterfield D.A. Beta-Amyloid peptide-derived, oxygen-dependent free radicals inhibit glutamate uptake in cultured astrocytes: Implications for Alzheimer's disease. Neuroreport 6 (1995) 1875-1879
83. Hashimoto K., Fujimura M., and Yamagami K. Dizocilpine-induced neuropathological changes in rat retrosplenial cortex are reversed by subsequent clozapine treatment. Life Sci. 66 (2000) 1071-1078
84. Hashimoto T., Bergen S.E., Nguyen Q.L., Xu B., Monteggia L.M., Pierri J.N., Sun Z., Sampson A.R., and Lewis D.A. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J. Neurosci. 25 (2005) 372-383
85. Hauber W. Clozapine improves dizocilpine-induced delayed alteration impairment in rats. J. Neural. Transm. Gen. Sect. 94 (1993) 223-233
86. Haynes L.E., Barber D., and Mitchell I.J. Chronic antidepressant medication attenuates dexamethasone-induced neuronal death and sublethal neuronal damage in the hippocampus and striatum. Brain Res. 1026 (2004) 157-167
87. He J., Xu H., Yang Y., Zhang X., and Li X.M. Neuroprotective effects of olanzapine on methamphetamine-induced neurotoxicity are associated with an inhibition of hyperthermia and prevention of Bcl-2 decrease in rats. Brain Res. 1018 (2004) 186-192
88. He J., Xu H., Yang Y., Zhang X., and Li X.M. Chronic administration of quetiapine alleviates the anxiety-like behavioural changes induced by neurotoxic regimen of dl-amphetamine in rats. Behav. Brain Res. 160 (2005) 178-187
89. He J., Yang Y., Xu H., Zhang X., and Li X.M. Olanzapine attenuates the okadaic acid-induced spatial memory impairment and hippocampal cell death in rats. Neuropsychopharmacology 30 (2005) 1511-1520
90. He J., Xu H., Yang Y., Rajakumar D., Li X., and Li X.M. The effects of chronic administration of quetiapine on the phencyclidine-induced reference memory impairment and decrease of Bcl-X(L)/Bax ratio in the posterior cingulate cortex in rats. Behav. Brain Res. 168 (2006) 236-242
91. Heckers S., Rauch S.L., Goff D., Savage C.R., Schacter D.L., Fischman A.J., and Alpert N.M. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. Nat. Neurosci. 1 (1998) 318-323
92. Hensley K., Carney J.M., Mattson M.P., Aksenova M., Harris M., Wu J.F., Floyd R.A., and Butterfield D.A. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer disease. Proc. Natl. Acad. Sci. USA 91 (1994) 3270-3274
93. Hirose S., and Ashby Jr. C.R. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. J. Clin. Psychiatry 63 (2002) 733-736
94. Hofer M., Pagliusi S.R., Hohn A., Leibrock J., and Barde Y.A. Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. EMBO J. 9 (1990) 2459-2464
95. Hohmann C.F., and Coyle J.T. Long-term effects of basal forebrain lesions on cholinergic, noradrenergic and serotonergic markers in mouse neocortex. Brain Res. Bull. 21 (1988) 13-20
96. Holson R.R., Webb P.J., Grafton T.F., and Hansen D.K. Prenatal neuroleptic exposure and growth stunting in the rat: An in vivo and in vitro examination of sensitive periods and possible mechanisms. Teratology 50 (1994) 125-136
97. Hrdlicka M. Combination of clozapine and maprotiline in refractory psychotic depression. Eur. Psychiatry 17 (2002) 484
98. Huang E.J., and Reichardt L.F. Neurotrophins: Roles in neuronal development and function. Annu. Rev. Neurosci. 24 (2001) 677-736
99. Humpel C., Wetmore C., and Olson L. Regulation of brain-derived neurotrophic factor messenger RNA and protein at the cellular level in pentylenetetrazol-induced epileptic seizures. Neuroscience 53 (1993) 909-918
100. Iritani S., Niizato K., Nawa H., Ikeda K., and Emson P.C. Immunohistochemical study of brain-derived neurotrophic factor and its receptor, TrkB, in the hippocampal formation of schizophrenic brains. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 (2003) 801-807
101. Ishak W.W., Rapaport M.H., and Gotto J.G. The effectiveness of atypical antipsychotic medications in depressive disorders. Curr. Psychiatry Rep. 6 (2004) 422-424
102. Jann M.W. Implications for atypical antipsychotics in the treatment of schizophrenia: Neurocognition effects and a neuroprotective hypothesis. Pharmacotherapy 24 (2004) 1759-1783
103. Jonsson S.A., Luts A., Guldberg-Kjaer N., and Ohman R. Pyramidal neuron size in the hippocampus of schizophrenics correlates with total cell count and degree of cell disarray. Eur. Arch. Psychiatry Clin. Neurosci. 249 (1999) 169-173
104. Jurand A., and Martin L.V. Teratogenic potential of two neurotropic drugs, haloperidol and dextromoramide, tested on mouse embryos. Teratology 42 (1990) 45-54
105. Kaneko M., Yokoyama F., Hoshino Y., Takahagi K., Murata S., Watanabe M., and Kumashiro H. Hypothalamic-pituitary-adrenal axis function in chronic schizophrenia: Association with clinical features. Neuropsychobiology 25 (1992) 1-7
106. Katoh-Semba R., Takeuchi I.K., Semba R., and Kato K. Distribution of brain-derived neurotrophic factor in rats and its changes with development in the brain. J. Neurochem. 69 (1997) 34-42
107. Keck Jr. P.E., Strakowski S.M., and McElroy S.L. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J. Clin. Psychiatry 61 Suppl. 3 (2000) 4-9
108. Keshavan M.S., Berger G., Zipursky R.B., Wood S.J., and Pantelis C. Neurobiology of early psychosis. Br. J. Psychiatry 187 Suppl. 48 (2005) s8-s18
109. Kippin T.E., Kapur S., and van der Kooy D. Dopamine specifically inhibits forebrain neural stem cell proliferation, suggesting a novel effect of antipsychotic drugs. J. Neurosci. 25 (2005) 5815-5823
110. Klein N., Sacher J., Wallner H., Tauscher J., and Kasper S. Therapy of treatment resistant depression: Focus on the management of TRD with atypical antipsychotics. CNS Spectr. 9 (2004) 823-832
111. Knable M.B., Barci B.M., Webster M.J., Meador-Woodruff J., Torrey E.F.,, and Stanley Neuropathology Consortium. Molecular abnormalities of the hippocampus in severe psychiatric illness: Postmortem findings from the Stanley Neuropathology Consortium. Mol. Psychiatry 9 (2004) 609-620
112. Kodama M., Fujioka T., and Duman R.S. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol. Psychiatry 56 (2004) 570-580
113. Krystal J.H., D'Souza D.C., Sanacora G., Goddard A.W., and Charney D.S. Current perspectives on the pathophysiology of schizophrenia, depression, and anxiety disorders. Med. Clin. North Am. 85 (2001) 559-577
114. Kuhn H.G., Winkler J., Kempermann G., Thal L.J., and Gage F.H. Epidermal growth factor and fibroblast growth factor-2 have different effects on neural progenitors in the adult rat brain. J. Neurosci. 17 (1997) 5820-5829
115. Lammers C.H., Garcia-Borreguero D., Schmider J., Gotthardt U., Dettling M., Holsboer F., and Heuser I.J. Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls: II. Biol. Psychiatry 38 (1995) 803-807
116. Largent B.L., Wikstrom H., Snowman A.M., and Snyder S.H. Novel antipsychotic drugs share high affinity for sigma receptors. Eur. J. Pharmacol. 155 (1988) 345-347
117. Lauder J.M. Hormonal and humoral influences on brain development. Psychoneuroendocrinology 8 (1983) 121-155
118. Lawlor M.A., and Alessi D.R. PKB/Akt: A key mediator of cell proliferation, survival and insulin responses?. J. Cell Sci. 114 (2001) 2903-2910
119. 2 generation and caspase 3-like protease activity. Immunopharmacol. Immunotoxicol. 24 (2002) 227-243
120. Li X.M., Chlan-Fourney J., Juorio A.V., Bennett V.L., Shrikhande S., Keegan D.L., Qi J., and Boulton A.A. Differential effects of olanzapine on the gene expression of superoxide dismutase and the low affinity nerve growth factor receptor. J. Neurosci. Res. 56 (1999) 72-75
121. Lindefors N., Brodin E., and Metsis M. Spatiotemporal selective effects on brain-derived neurotrophic factor and trkB messenger RNA in rat hippocampus by electroconvulsive shock. Neuroscience 65 (1995) 661-670
122. Linden A.M., Vaisanen J., Lakso M., Nawa H., Wong G., and Castren E. Expression of neurotrophins BDNF and NT-3, and their receptors in rat brain after administration of antipsychotic and psychotrophic agents. J. Mol. Neurosci. 14 (2000) 27-37
123. Lindenmayer J.P. New pharmacotherapeutic modalities for negative symptoms in psychosis. Acta Psychiatr. Scand. Suppl. 388 (1995) 15-19
124. Lipska B.K., Khaing Z.Z., Weickert C.S., and Weinberger D.R. BDNF mRNA expression in rat hippocampus and prefrontal cortex: Effects of neonatal ventral hippocampal damage and antipsychotic drugs. Eur. J. Neurosci. 14 (2001) 135-144
125. Lu X.H., and Dwyer D.S. Second-generation antipsychotic drugs, olanzapine, quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via PI3K/AKT, ERK, and pertussis toxin-sensitive pathways. J. Mol. Neurosci. 27 (2005) 43-64
126. Lu X.H., Bradley R.J., and Dwyer D.S. Olanzapine produces trophic effects in vitro and stimulates phosphorylation of Akt/PKB, ERK1/2, and the mitogen-activated protein kinase p38. Brain Res. 1011 (2004) 58-68
127. Luo C., Xu H., and Li X.M. Post-stress changes in BDNF and Bcl-2 immuno-reactivities in hippocampal neurons: Effect of chronic administration of olanzapine. Brain Res. 1025 (2004) 194-202
128. Luo C., Xu H., and Li X.M. Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress. Brain Res. 1063 (2005) 32-39
129. Lyne J., Kelly B.D., and O'Connor W.T. Schizophrenia: A review of neuropharmacology. Ir. J. Med. Sci. 173 (2004) 155-159
130. Malaspina D., Perera G.M., Lignelli A., Marshall R.S., Esser P.D., Storer S., Furman V., Wray A.D., Coleman E., Gorman J.M., and Van Heertum R.L. SPECT imaging of odor identification in schizophrenia. Psychiatry Res. 82 (1998) 53-61
131. Mann K., Rossbach W., Muller M.J., Muller-Siecheneder F., Pott T., Linde I., Dittmann R.W., and Hiemke C. Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine. Psychoneuroendocrinology 31 (2006) 256-264
132. Maragnoli M.E., Fumagalli F., Gennarelli M., Racagni G., and Riva M.A. Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain. Biol. Psychiatry 55 (2004) 1095-1102
133. Martin M.V., Dong H., Bertchume A., and Csernansky J.G. Low dose quetiapine reverses deficits in contextual and cued fear conditioning in rats with excitotoxin-induced hippocampal neuropathy. Pharmacol. Biochem. Behav. 82 (2005) 263-269
134. Matthews J.D., Bottonari K.A., Polania L.M., Mischoulon D., Dording C.M., Irvin R., and Fava M. An open study of olanzapine and fluoxetine for psychotic major depressive disorder: Interim analyses. J. Clin. Psychiatry 63 (2002) 1164-1170
135. McCollum A.T., and Estus S. NGF acts via p75 low-affinity neurotrophin receptor and calpain inhibition to reduce UV neurotoxicity. J. Neurosci. Res. 77 (2004) 552-564
136. McIlroy S., and Craig D. Neurobiology and genetics of behavioural syndromes of Alzheimer's disease. Curr. Alzheimer Res. 1 (2004) 135-142
137. McIntyre R., and Katzman M. The role of atypical antipsychotics in bipolar depression and anxiety disorders. Bipolar Disord. 5 Suppl. 2 (2003) 20-35
138. McIntyre R.S., Mancini D.A., Lin P., and Jordan J. Treating bipolar disorder. Evidence-based guidelines for family medicine. Can. Fam. Physician 50 (2004) 388-394
139. Mehlen P., and Bredesen D.E. The dependence receptor hypothesis. Apoptosis 9 (2004) 37-49
140. Meier A., Neumann A.C., Jordan W., Huether G., Rodenbeck A., Ruther E., and Cohrs S. Ziprasidone decreases cortisol excretion in healthy subjects. Br. J. Clin. Pharmacol. 60 (2005) 330-336
141. Meltzer H.Y., Lee M.A., and Ranjan R. Recent advances in the pharmacotherapy of schizophrenia. Acta Psychiatr. Scand. Suppl. 384 (1994) 95-101
142. Meltzer H.Y., Park S., and Kessler R. Cognition, schizophrenia, and the atypical antipsychotic drugs. Proc. Natl. Acad. Sci. USA 96 (1999) 13591-13593
143. Meredith G.E., Switzer III R.C., and Napier T.C. Short-term, D2 receptor blockade induces synaptic degeneration, reduces levels of tyrosine hydroxylase and brain-derived neurotrophic factor, and enhances D2-mediated firing in the ventral pallidum. Brain Res. 995 (2004) 14-22
144. Ming G.L., and Song H. Adult neurogenesis in the mammalian central nervous system. Annu. Rev. Neurosci. 28 (2005) 223-250
145. Miyamoto S., LaMantia A.S., Duncan G.E., Sullivan P., Gilmore J.H., and Lieberman J.A. Recent advances in the neurobiology of schizophrenia. Mol. Interv. 3 (2003) 27-39
146. Miyamoto S., Duncan G.E., Marx C.E., and Lieberman J.A. Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10 (2005) 79-104
147. Mobley W.C., Rutkowski J.L., Tennekoon G.I., Gemski J., Buchanan K., and Johnston M.V. Nerve growth factor increases choline acetyltransferase activity in developing basal forebrain neurons. Brain Res. 387 (1986) 53-62
148. Nagtegaal I.D., Lakke E.A., and Marani E. Trophic and tropic factors in the development of the central nervous system. Arch. Physiol. Biochem. 106 (1998) 161-202
149. Nakagawa S., Kim J.E., Lee R., Malberg J.E., Chen J., Steffen C., Zhang Y.J., Nestler E.J., and Duman R.S. Regulation of neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein. J. Neurosci. 22 (2002) 3673-3682
150. Negron A.E., and Reichman W.E. Risperidone in the treatment of patients with Alzheimer's disease with negative symptoms. Int. Psychogeriatr. 12 (2000) 527-536
151. Newman-Tancredi A., Gavaudan S., Conte C., Chaput C., Touzard M., Verriele L., Audinot V., and Millan M.J. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: A [35S]GTPgammaS binding study. Eur. J. Pharmacol. 355 (1998) 245-256
152. Newman-Tancredi A., Verriele L., Touzard M., and Millan M.J. Efficacy of antipsychotic agents at human 5-HT(1A) receptors determined by [3H]WAY100,635 binding affinity ratios: Relationship to efficacy for G-protein activation. Eur. J. Pharmacol. 428 (2001) 177-184
153. Nibuya M., Morinobu S., and Duman R.S. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J. Neurosci. 15 (1995) 7539-7547
154. Nibuya M., Nestler E.J., and Duman R.S. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J. Neurosci. 16 (1996) 2365-2372
155. Nyback H., and Sedvall G. Effects of neuroleptics on striatal dopamine synthesized from 14C-tyrosine. Pharmacol. Ther. [B] 2 (1976) 49-63
156. Okamura N., Hashimoto K., Kanahara N., Shimizu E., Kumakiri C., Komatsu N., and Iyo M. Protective effect of the antipsychotic drug zotepine on dizocilpine-induced neuropathological changes in rat retrosplenial cortex. Eur. J. Pharmacol. 461 (2003) 93-98
157. Olney J.W., Labruyere J., and Price M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244 (1989) 1360-1362
158. Ozaki T. Comparative effects of dopamine D(1) and D(2) receptor antagonists on nerve growth factor protein induction. Eur. J. Pharmacol. 402 (2000) 39-44
159. Ozaki T., Mui K., and Yamagami S. Comparison of the effects of dopamine D1 and D2 receptor antagonists on nerve growth factor mRNA expression. Eur. J. Pharmacol. 369 (1999) 133-143
160. Palmer T.D., Takahashi J., and Gage F.H. The adult rat hippocampus contains primordial neural stem cells. Mol. Cell Neurosci. 8 (1997) 389-404
161. Parikh V., Khan M.M., Terry A., and Mahadik S.P. Differential effects of typical and atypical antipsychotics on nerve growth factor and choline acetyltransferase expression in the cortex and nucleus basalis of rats. J. Psychiatr. Res. 38 (2004) 521-529
162. Parikh V., Terry A.V., Khan M.M., and Mahadik S.P. Modulation of nerve growth factor and choline acetyltransferase expression in rat hippocampus after chronic exposure to haloperidol, risperidone, and olanzapine. Psychopharmacology (Berl.) 172 (2004) 365-374
163. Patel A.J., and Lewis P.D. Brain cell acquisition and neurotropic drugs with special reference to functional teratogenesis. Prog. Brain Res. 73 (1988) 389-403
164. Pencea V., Bingaman K.D., Wiegand S.J., and Luskin M.B. Infusion of brain-derived neurotrophic factor into the lateral ventricle of the adult rat leads to new neurons in the parenchyma of the striatum, septum, thalamus, and hypothalamus. J. Neurosci. 21 (2001) 6706-6717
165. Perenyi A., and Forlano R. Suicide in schizophrenia. Neuropsychopharmacol. Hung. 7 (2005) 107-117
166. Pirildar S., Gonul A.S., Taneli F., and Akdeniz F. Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 28 (2004) 709-713
167. Pitchot W., and Ansseau M. Addition of olanzapine for treatment-resistant depression. Am. J. Psychiatry 158 (2001) 1737-1738
168. +-induced apoptosis. Eur. J. Neurosci. 17 (2003) 1563-1570
169. Rabizadeh S., and Bredesen D.E. Ten years on: Mediation of cell death by the common neurotrophin receptor p75(NTR). Cytokine Growth Factor Rev. 14 (2003) 225-239
170. Radley J.J., and Jacobs B.L. 5-HT1A receptor antagonist administration decreases cell proliferation in the dentate gyrus. Brain Res. 955 (2002) 264-267
171. Raedler T.J., Knable M.B., and Weinberger D.R. Schizophrenia as a developmental disorder of the cerebral cortex. Curr. Opin. Neurobiol. 8 (1998) 157-161
172. Rankin G.O., Valentovic M.A., Teets V.J., Nicoll D.W., Sutherland C.H., and Brown P.I. Effect of calcium antagonism by nifedipine and chlorpromazine on acute N-(3,5-dichlorophenyl)succinimide-induced nephrotoxicity in Fischer 344 rats. Toxicology 66 (1991) 19-34
173. Richelson E. Receptor pharmacology of neuroleptics: Relation to clinical effects. J. Clin. Psychiatry 60 Suppl. 10 (1999) 5-14
174. Ritsner M., Maayan R., Gibel A., Strous R.D., Modai I., and Weizman A. Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients. Eur. Neuropsychopharmacol. 14 (2004) 267-273
175. Ritsner M., Gibel A., Maayan R., Ratner Y., Ram E., Biadsy H., Modai I., and Weizman A. Cortisol/dehydroepiandrosterone ratio and responses to antipsychotic treatment in schizophrenia. Neuropsychopharmacology 30 (2005) 1913-1922
176. Riva M.A., Molteni R., Tascedda F., Massironi A., and Racagni G. Selective modulation of fibroblast growth factor-2 expression in the rat brain by the atypical antipsychotic clozapine. Neuropharmacology 38 (1999) 1075-1082
177. Rogers H.J., and Lietman P.S. Effect of folate and folinate on 3H-thymidine incorporation by transforming human lymphocytes in vitro. Experientia 33 (1977) 671-672
178. Roux P.P., and Barker P.A. Neurotrophin signaling through the p75 neurotrophin receptor. Prog. Neurobiol. 67 (2002) 203-233
179. Ryan M.C., Sharifi N., Condren R., and Thakore J.H. Evidence of basal pituitary-adrenal overactivity in first episode, drug naive patients with schizophrenia. Psychoneuroendocrinology 29 (2004) 1065-1070
180. Sagara Y. Induction of reactive oxygen species in neurons by haloperidol. J. Neurochem. 71 (1998) 1002-1012
181. Sajatovic M., Mullen J.A., and Sweitzer D.E. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J. Clin. Psychiatry 63 (2002) 1156-1163
182. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., Weisstaub N., Lee J., Duman R., Arancio O., Belzung C., and Hen R. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301 (2003) 805-809
183. Saville J.G., Davidson C.P., D'Adrea G.H., Born C.K., and Hamrick M.E. Inhibition of acetaminophen hepatotoxicity by chlorpromazine in fed and fasted mice. Biochem. Pharmacol. 37 (1988) 2467-2471
184. Scharfman H., Goodman J., Macleod A., Phani S., Antonelli C., and Croll S. Increased neurogenesis and the ectopic granule cells after intrahippocampal BDNF infusion in adult rats. Exp. Neurol. 192 (2005) 348-356
185. Schmitt A., Weber S., Jatzko A., Braus D.F., and Henn F.A. Hippocampal volume and cell proliferation after acute and chronic clozapine or haloperidol treatment. J. Neural. Transm. 111 (2004) 91-100
186. Schramm M., Falkai P., Feldmann N., Knable M.B., and Bayer T.A. Reduced tyrosine kinase receptor C mRNA levels in the frontal cortex of patients with schizophrenia. Neurosci. Lett. 257 (1998) 65-68
187. Sharif Z.A. Treatment refractory schizophrenia: How should we proceed?. Psychiatr. Q. 69 (1998) 263-281
188. Shimizu E., Hashimoto K., Watanabe H., Komatsu N., Okamura N., Koike K., Shinoda N., Nakazato M., Kumakiri C., Okada S., and Iyo M. Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neurosci. Lett. 351 (2003) 111-114
189. Shinosaki K., Nishikawa T., and Takeda M. Neurobiological basis of behavioral and psychological symptoms in dementia of the Alzheimer type. Psychiatry Clin. Neurosci. 54 (2000) 611-620
190. Shors T.J. Memory traces of trace memories: Neurogenesis, synaptogenesis and awareness. Trends Neurosci. 27 (2004) 250-256
191. Shors T.J., Miesegaes G., Beylin A., Zhao M., Rydel T., and Gould E. Neurogenesis in the adult is involved in the formation of trace memories. Nature 410 (2001) 372-376
192. Siddiqui Z., Ramaswamy S., and Petty F. Quetiapine therapy for corticosteroid-induced mania. Can. J. Psychiatry 50 (2005) 77-78
193. Smith M.A., Makino S., Kvetnansky R., and Post R.M. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J. Neurosci. 15 (1995) 1768-1777
194. Stein M.B., Kline N.A., and Matloff J.L. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: A double-blind, placebo-controlled study. Am. J. Psychiatry 159 (2002) 1777-1779
195. Taherianfard M., and Shariaty M. Evaluation of serum steroid hormones in schizophrenic patients. Indian J. Med. Sci. 58 (2004) 3-9
196. Takahashi M., Shirakawa O., Toyooka K., Kitamura N., Hashimoto T., Maeda K., Koizumi S., Wakabayashi K., Takahashi H., Someya T., and Nawa H. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol. Psychiatry 5 (2000) 293-300
197. Tani K., Takei N., Kawai M., Suzuki K., Sekine Y., Toyoda T., Minabe Y., and Mori N. Augmentation of milnacipran by risperidone in treatment for major depression. Int. J. Neuropsychopharmacol. 7 (2004) 55-58
198. Tao Y., Black I.B., and DiCicco-Bloom E. In vivo neurogenesis is inhibited by neutralizing antibodies to basic fibroblast growth factor. J. Neurobiol. 33 (1997) 289-296
199. Tatsumi M., Jansen K., Blakely R.D., and Richelson E. Pharmacological profile of neuroleptics at human monoamine transporters. Eur. J. Pharmacol. 368 (1999) 277-283
200. Toyooka K., Asama K., Watanabe Y., Muratake T., Takahashi M., Someya T., and Nawa H. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res. 110 (2002) 249-257
201. 2+ uptake induced by amyloid beta protein (25-35) in vitro. Brain Res. 748 (1997) 184-188
202. Ukai W., Ozawa H., Tateno M., Hashimoto E., and Saito T. Neurotoxic potential of haloperidol in comparison with risperidone: Implication of Akt-mediated signal changes by haloperidol. J. Neural. Transm. 111 (2004) 667-681
203. Vaidya V.A., and Duman R.S. Depresssion-emerging insights from neurobiology. Br. Med. Bull. 57 (2001) 61-79
204. Vaidya V.A., Marek G.J., Aghajanian G.K., and Duman R.S. 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J. Neurosci. 17 (1997) 2785-2795
205. van Praag H., Schinder A.F., Christie B.R., Toni N., Palmer T.D., and Gage F.H. Functional neurogenesis in the adult hippocampus. Nature 415 (2002) 1030-1034
206. Vaudry D., Stork P.J., Lazarovici P., and Eiden L.E. Signaling pathways for PC12 cell differentiation: Making the right connections. Science 296 (2002) 1648-1649
207. Wakade C.G., Mahadik S.P., Waller J.L., and Chiu F.C. Atypical neuroleptics stimulate neurogenesis in adult rat brain. J. Neurosci. Res. 69 (2002) 72-79
208. Wang H., Xu H., Dyck L., and Li X.M. Atypical antipsychotics protect PC12 cells against amyloid-induced apoptosis by inhibiting oxidative stress. J. Neurosci. Res. 81 (2005) 572-580
209. Wang H.D., Dunnavant F.D., Jarman T., and Deutch A.Y. Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. Neuropsychopharmacology 29 (2004) 1230-1238
210. Weber C.M., Eke B.C., and Maines M.D. Corticosterone regulates heme oxygenase-2 and NO synthase transcription and protein expression in rat brain. J. Neurochem. 63 (1994) 953-962
211. Weber E., Sonders M., Quarum M., McLean S., Pou S., and Keana J.F. 1,3-Di(2-[5-3H]tolyl)guanidine: A selective ligand that labels sigma-type receptors for psychotomimetic opiates and antipsychotic drugs. Proc. Natl. Acad. Sci. USA 83 (1986) 8784-8788
212. Wei Z., Bai O., Richardson J.S., Mousseau D.D., and Li X.M. Olanzapine protects PC12 cells from oxidative stress induced by hydrogen Peroxide. J. Neurosci. Res. 73 (2003) 364-368
213. L/S expression and localization. J. Neurosci. Res. 74 (2003) 942-947
214. Weickert C.S., Hyde T.M., Lipska B.K., Herman M.M., Weinberger D.R., and Kleinman J.E. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol. Psychiatry 8 (2003) 592-610
215. Weickert C.S., Ligons D.L., Romanczyk T., Ungaro G., Hyde T.M., Herman M.M., Weinberger D.R., and Kleinman J.E. Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Mol. Psychiatry 10 (2005) 637-650
216. Weinberger D.R. Cell biology of the hippocampal formation in schizophrenia. Biol. Psychiatry 45 (1999) 395-402
217. Weinberger D.R., and Gallhofer B. Cognitive function in schizophrenia. Int. Clin. Psychopharmacol. 12 Suppl. 4 (1997) S29-S36
218. Weiss E.M., Bilder R.M., and Fleischhacker W.W. The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia. Psychopharmacology (Berl.) 162 (2002) 11-17
219. Wetmore C., Ernfors P., Persson H., and Olson L. Localization of brain-derived neurotrophic factor mRNA to neurons in the brain by in situ hybridization. Exp. Neurol. 109 (1990) 141-152
220. Wetmore C., Olson L., and Bean A.J. Regulation of brain-derived neurotrophic factor (BDNF) expression and release from hippocampal neurons is mediated by non-NMDA type glutamate receptors. J. Neurosci. 14 (1994) 1688-1700
221. Whitaker-Azmitia P.M., and Azmitia E.C. Stimulation of astroglial serotonin receptors produces culture media which regulates growth of serotonergic neurons. Brain Res. 497 (1989) 80-85
222. Wik G. Effects of neuroleptic treatment on cortisol and 3-methoxy-4-hydroxyphenylethyl glycol levels in blood. J. Endocrinol. 144 (1995) 425-429
223. Williams R., Ali S.F., Scalzo F.M., Soliman K., and Holson R.R. Prenatal haloperidol exposure: Effects on brain weights and caudate neurotransmitter levels in rats. Brain Res. Bull. 29 (1992) 449-458
224. Wright I.C., Rabe-Hesketh S., Woodruff P.W., David A.S., Murray R.M., and Bullmore E.T. Meta-analysis of regional brain volumes in schizophrenia. Am. J. Psychiatry 157 (2000) 16-25
225. Xiao X.Q., Zhang H.Y., and Tang X.C. Huperzine A attenuates amyloid beta-peptide fragment 25-35-induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase-3 activation. J. Neurosci. Res. 67 (2002) 30-36
226. Xu H., Qing H., Lu W., Keegan D., Richardson J.S., and Li X.M. Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus. Neurosci. Lett. 321 (2002) 65-68
227. Xu H., Luo C., Richardson J.S., and Li X.M. Recovery of hippocampal cell proliferation and BDNF levels, both of which are reduced by repeated restraint stress, is accelerated by chronic venlafaxine. Pharmacogenomics J. 4 (2004) 322-331
228. Xu H., Chen Z., He J., Haimanot S., Li X., Dyck L., and Li X.M. Synergetic effects of quetiapine and venlafaxine in preventing the chronic restraint stress-induced decrease in cell proliferation and BDNF expression in rat hippocampus. Hippocampus 16 6 (2006) 551-559
229. Yang B.H., Son H., Kim S.H., Nam J.H., Choi J.H., and Lee J.S. Phosphorylation of ERK and CREB in cultured hippocampal neurons after haloperidol and risperidone administration. Psychiatry Clin. Neurosci. 58 (2004) 262-267
230. Yao J.K., Reddy R.D., and van Kammen D.P. Oxidative damage and schizophrenia: An overview of the evidence and its therapeutic implications. CNS Drugs 15 (2001) 287-310
231. Yuen E.C., and Mobley W.C. Therapeutic potential of neurotrophic factors for neurological disorders. Ann. Neurol. 40 (1996) 346-354
232. Zhang X.Y., Zhou D.F., Cao L.Y., Wu G.Y., and Shen Y.C. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: Association with psychopathology and response to antipsychotics. Neuropsychopharmacology 30 (2005) 1532-1538
233. Zhu D.Y., Lau L., Liu S.H., Wei J.S., and Lu Y.M. Activation of cAMP-response-element-binding protein (CREB) after focal cerebral ischemia stimulates neurogenesis in the adult dentate gyrus. Proc. Natl. Acad. Sci. USA 101 (2004) 9453-9457
234. Zubenko G.S. Molecular neurobiology of Alzheimer's disease (syndrome?). Harv. Rev. Psychiatry 5 (1997) 177-213